NASDAQ : ICCC
ImmuCell Corporation — Key statistics
Healthcare · Biotechnology · United States
Last price 10.26 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 93.18M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 94.09M |
| Enterprise Value | 97.68M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 9.08M |
| Shares Outstanding | 9.08M |
| Shares Change (YoY) | +3.49% |
| Shares Change (QoQ) | +1.58% |
| Owned by Insiders (%) | 28.05% |
| Owned by Institutions (%) | 19.03% |
| Float | 6.03M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 138.93 |
| Forward PE | n/a |
| PS Ratio | 3.09 |
| Forward PS | n/a |
| PB Ratio | 2.97 |
| P/TBV Ratio | 3.03 |
| P/FCF Ratio | 22.45 |
| P/OCF Ratio | 16.06 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 124.75 |
| EV / Sales | 3.20 |
| EV / EBITDA | 13.93 |
| EV / EBIT | 21.05 |
| EV / FCF | 23.31 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.75 |
| Quick Ratio | 2.65 |
| Debt / Equity | 0.40 |
| Debt / EBITDA | 1.66 |
| Debt / FCF | 2.95 |
| Interest Coverage | 10.70 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 2.57% |
| Return on Assets (ROA) | 6.25% |
| Return on Invested Capital (ROIC) | 12.29% |
| Return on Capital Employed (ROCE) | 11.06% |
| Weighted Average Cost of Capital (WACC) | 6.91% |
| Revenue Per Employee | $420,213 |
| Profits Per Employee | $10,786 |
| Employee Count | 73 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 2.11 |
Taxes
| Measure | Value |
|---|
| Income Tax | 66,233 |
| Effective Tax Rate | 7.76% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.57 |
| 52-Week Price Change | +64.45% |
| 50-Day Moving Average | 10.04 |
| 200-Day Moving Average | 8.88 |
| Relative Strength Index (RSI) | 50.49 |
| Average Volume (20 Days) | 7,732 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 18,103 |
| Short Previous Month | 22,112 |
| Short % of Shares Out | 0.20% |
| Short % of Float | 0.30% |
| Short Ratio (days to cover) | 1.34 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 30.68M |
| Gross Profit | 12.37M |
| Operating Income | 4.67M |
| Pretax Income | 853,606 |
| Net Income | 787,373 |
| EBITDA | 7.05M |
| EBIT | 4.67M |
| Earnings Per Share (EPS) | $0.07 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 8.86M |
| Total Debt | 12.45M |
| Net Cash | -3.59M |
| Net Cash Per Share | -$0.39 |
| Equity (Book Value) | 31.37M |
| Book Value Per Share | 3.45 |
| Working Capital | 16.64M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 5.89M |
| Capital Expenditures | -1.68M |
| Depreciation & Amortization | 2.38M |
| Net Borrowing | -1.52M |
| Free Cash Flow | 4.21M |
| FCF Per Share | $0.46 |
Margins
| Measure | Value |
|---|
| Gross Margin | 40.32% |
| Operating Margin | 15.21% |
| Pretax Margin | 2.78% |
| Profit Margin | 2.57% |
| EBITDA Margin | 22.98% |
| EBIT Margin | 15.21% |
| FCF Margin | 13.74% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.49% |
| Shareholder Yield | -3.49% |
| Earnings Yield | 0.72% |
| FCF Yield | 4.45% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.51 |
| Piotroski F-Score | 8 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |